{"related:QbihN5kvkFMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5":[{"title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a …","url":"https://www.sciencedirect.com/science/article/pii/S1470204519304139","authors":["RJ Motzer","RJ Motzer BI Rini","RJ Motzer BI Rini DF McDermott","RJ Motzer BI Rini DF McDermott OA Frontera…"],"year":2019,"numCitations":99,"pdf":"https://researchers.mq.edu.au/en/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-first-line-treatmen","citationUrl":"http://scholar.google.com/scholar?cites=6021365036904200257&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:QbihN5kvkFMJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6021365036904200257&hl=en&as_sdt=0,5","publication":"Elsevier","p":1,"exp":1596898400082},{"title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a …","url":"https://ereprints.elsevier.es/sites/es.ereprints.elsevier.cc/files/filefield_paths/motzer_en.pdf","authors":["BI Rini","BI Rini DF McDermott","BI Rini DF McDermott OA Frontera","BI Rini DF McDermott OA Frontera HJ Hammers…"],"year":2019,"numCitations":0,"pdf":"https://es.ereprints.elsevier.cc/sites/es.ereprints.elsevier.cc/files/filefield_paths/motzer_en.pdf","relatedUrl":"http://scholar.google.com/scholar?q=related:KWt0OdXpcMcJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14371243512940489513&hl=en&as_sdt=0,5","publication":"ereprints.elsevier.es"},{"title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase …","url":"https://www.sciencedirect.com/science/article/pii/S0140673619307238","authors":["BI Rini","BI Rini T Powles","BI Rini T Powles MB Atkins","BI Rini T Powles MB Atkins B Escudier…"],"year":2019,"numCitations":181,"pdf":"https://researchers.mq.edu.au/en/publications/atezolizumab-plus-bevacizumab-versus-sunitinib-in-patients-with-p","citationUrl":"http://scholar.google.com/scholar?cites=16381744679535091864&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:mKDV6P2lV-MJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16381744679535091864&hl=en&as_sdt=0,5","publication":"Elsevier"},{"title":"CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell …","url":"https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4513","authors":["DF McDermott","DF McDermott TK Choueiri","DF McDermott TK Choueiri RJ Motzer","DF McDermott TK Choueiri RJ Motzer OR Aren…"],"year":2019,"numCitations":36,"citationUrl":"http://scholar.google.com/scholar?cites=2799931541079386205&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Xehy5eZa2yYJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","publication":"ascopubs.org"},{"title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816047","authors":["RJ Motzer","RJ Motzer K Penkov","RJ Motzer K Penkov J Haanen","RJ Motzer K Penkov J Haanen B Rini…"],"year":2019,"numCitations":502,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816047","citationUrl":"http://scholar.google.com/scholar?cites=1882792696390332365&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:za8LXvsFIRoJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1882792696390332365&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816714","authors":["BI Rini","BI Rini ER Plimack","BI Rini ER Plimack V Stus","BI Rini ER Plimack V Stus R Gafanov…"],"year":2019,"numCitations":545,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816714","citationUrl":"http://scholar.google.com/scholar?cites=14370914940926626173&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:fQlJl_--b8cJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14370914940926626173&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC …","url":"https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4500","authors":["BI Rini","BI Rini ER Plimack","BI Rini ER Plimack V Stus","BI Rini ER Plimack V Stus R Gafanov","BI Rini ER Plimack V Stus R Gafanov R Hawkins…"],"year":2019,"numCitations":31,"citationUrl":"http://scholar.google.com/scholar?cites=6374177870072302704&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:cMzQQAChdVgJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6374177870072302704&hl=en&as_sdt=0,5","publication":"ascopubs.org"},{"title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial) …","url":"https://www.sciencedirect.com/science/article/pii/S0959804918301813","authors":["TK Choueiri","TK Choueiri C Hessel","TK Choueiri C Hessel S Halabi","TK Choueiri C Hessel S Halabi B Sanford…"],"year":2018,"numCitations":121,"pdf":"https://www.sciencedirect.com/science/article/pii/S0959804918301813","citationUrl":"http://scholar.google.com/scholar?cites=14929455411752643417&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:WauM65gUMM8J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14929455411752643417&hl=en&as_sdt=0,5","publication":"Elsevier"},{"title":"Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic …","url":"https://www.sciencedirect.com/science/article/pii/S0302283819304269","authors":["L Albiges","L Albiges T Powles","L Albiges T Powles M Staehler","L Albiges T Powles M Staehler K Bensalah","L Albiges T Powles M Staehler K Bensalah RH Giles…"],"year":2019,"numCitations":48,"pdf":"https://www.researchgate.net/profile/Thomas_Lam5/publication/333671322_Updated_European_Association_of_Urology_Guidelines_on_Renal_Cell_Carcinoma_Immune_Checkpoint_Inhibition_Is_the_New_Backbone_in_First-line_Treatment_of_Metastatic_Clear-cell_Renal_Cell_Carcinoma/links/5cfd92d392851c874c5b4fc7/Updated-European-Association-of-Urology-Guidelines-on-Renal-Cell-Carcinoma-Immune-Checkpoint-Inhibition-Is-the-New-Backbone-in-First-line-Treatment-of-Metastatic-Clear-cell-Renal-Cell-Carcinoma.pdf","citationUrl":"http://scholar.google.com/scholar?cites=1736679606747912938&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:6trfqObsGRgJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1736679606747912938&hl=en&as_sdt=0,5","publication":"Elsevier"},{"title":"Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A+ Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).","url":"https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.544","authors":["TK Choueiri","TK Choueiri RJ Motzer","TK Choueiri RJ Motzer MT Campbell","TK Choueiri RJ Motzer MT Campbell BY Alekseev…"],"year":2019,"numCitations":15,"citationUrl":"http://scholar.google.com/scholar?cites=721999296254568645&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:xehV3YgOBQoJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","publication":"ascopubs.org"}]}